Ultragenyx Pharmaceutical | RARE - Beneficio Bruto En Ventas

Precio De Mercado
19.87
Cambio Diario
-0.55 -2.69%
Mensual
-11.73%
Anual
-49.29%
Q1 Expectativa
19.27




Beneficio Bruto En Ventas Cambio Fecha
Acadia Pharmaceuticals USD 257.76M 778K 2025-12
Agios Pharmaceuticals USD 18.09M 6.89M 2025-12
Alnylam Pharmaceuticals USD 829.31M 219.56M 2025-12
BioCryst Pharmaceuticals USD 153.05M 4.16M 2025-12
BioMarin Pharmaceutical USD 713.01M 81.81M 2025-12
Esperion Therapeutics USD 140.59M 94.57M 2025-12
Immunic 0 0 2025-03
Insmed USD 217.69M 106.25M 2025-12
Ionis Pharmaceuticals USD 195M 40M 2025-12
Karyopharm Therapeutics USD -30.78M 1.29M 2024-12
Kyowa Hakko Kirin JPY 109.5B 18.9B 2025-12
MacroGenics USD 31.11M 30.14M 2025-12
Moderna USD 226M 583M 2025-12
Neurocrine Biosciences USD 787.9M 7M 2025-12
PTC Therapeutics USD 148.38M 39.31M 2025-12
Puma Biotechnology USD 20.32M 24.85M 2024-09
Regeneron Pharmaceuticals USD 3.3B 67M 2025-12
Sarepta Therapeutics USD 43.55M 204.36M 2025-12
Ultragenyx Pharmaceutical USD 178M 46.06M 2025-12
Vertex Pharmaceuticals USD 2.72B 62.4M 2025-12
Xoma 992K 846K 2024-06